Mathias Uhlen - Novozymes Independent Director
| NVZMY Stock | USD 54.45 0.18 0.33% |
Director
Mr. Mathias Uhlen was Independent Member of the Board of Directors at Novozymes AS since 2007. He is Professor at the Royal Institute of Technology in Stockholm, Sweden and the Technical University of Denmark . He is also Chairman of the Board of Directors at Antibodypedia AB, ScandiBio Therapeutics AB and Atlas Antibodies AB, as well as Vice Chairman of the Board of Directors at Affibody Medical AB. He also acts as Member of the Board of Bure Equity AB. He has experience in research and biotechnology. since 2007.
| Age | 63 |
| Tenure | 17 years |
| Phone | 45 44 46 00 00 |
| Web | https://www.novozymes.com |
Novozymes Management Efficiency
The company has return on total asset (ROA) of 0.1062 % which means that it generated a profit of $0.1062 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2789 %, meaning that it generated $0.2789 on every $100 dollars invested by stockholders. Novozymes' management efficiency ratios could be used to measure how well Novozymes manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Tracy McKibben | Ecolab Inc | 51 | |
| Sian HerbertJones | Air Liquide SA | 56 | |
| Rizza Sia | Dupont De Nemours | 27 | |
| Matthew Paull | Air Products and | 69 | |
| Thierry Peugeot | Air Liquide SA | 58 | |
| Fred Lowery | Dupont De Nemours | N/A | |
| James Gallogly | Dupont De Nemours | 63 | |
| Robert Brown | Dupont De Nemours | 65 | |
| Pierre Dufour | Air Liquide SA | 61 | |
| HingYuen Ho | Air Products and | 61 | |
| Martin Richenhagen | PPG Industries | 68 | |
| Victoria Haynes | PPG Industries | 72 | |
| William Untiong | Dupont De Nemours | 63 | |
| Chadwick Deaton | Air Products and | 68 | |
| Suzanne Vautrinot | Ecolab Inc | 61 | |
| Stephen Angel | PPG Industries | 65 | |
| Steven Wunning | Sherwin Williams Co | 69 | |
| Shari Ballard | Ecolab Inc | 54 | |
| Lee Thomas | Dupont De Nemours | 72 | |
| Eleuthere Pont | Dupont De Nemours | 53 | |
| Kerrii Anderson | Sherwin Williams Co | 63 | |
Management Performance
| Return On Equity | 0.28 | |||
| Return On Asset | 0.11 |
Novozymes AS Leadership Team
Elected by the shareholders, the Novozymes' board of directors comprises two types of representatives: Novozymes inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novozymes. The board's role is to monitor Novozymes' management team and ensure that shareholders' interests are well served. Novozymes' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novozymes' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Videbaek, COO and Executive VP of Bus. Devel. | ||
| Tobias Bjorklund, Head of Investor Relations | ||
| Ester Baiget, Pres CEO | ||
| Kasim Kutay, Director | ||
| Anders Lund, Executive Vice President Household Care & Technical Industries | ||
| Agnete RaaschouNielsen, Director | ||
| Thomas Nagy, Executive VP of Supply Operations | ||
| Pedro Fernandes, Head America | ||
| Joergen Rasmussen, Independent Director | ||
| Andrew Fordyce, Executive VP of Food and Beverages | ||
| Lena Halskov, Director, Employee Representative | ||
| Tue Micheelsen, VP Marketing | ||
| Sebastian Sderberg, VP Acquisitions | ||
| Martin Riise, Head of Investor Relations | ||
| Peder Nielsen, CEO and Pres | ||
| Prisca HavranekKosicek, CFO & Executive Vice President Corporate Functions | ||
| HeinzJuergen Bertram, Independent Director | ||
| Benny Loft, CFO and Executive VP | ||
| Anders Knudsen, Director, Employee Representative | ||
| Lena Olving, Independent Director | ||
| Mathias Uhlen, Independent Director | ||
| Graziela Malucelli, Supply Operations | ||
| Patricia Malarkey, Director | ||
| Henrik Gurtler, Chairman of the Board | ||
| Per Falholt, Consultant | ||
| Kim Stratton, Director | ||
| Tina Fanoe, Executive Vice President Agriculture & Bioenergy | ||
| Morten Rasmussen, Sustainability People | ||
| Thomas Bomhoff, Head of Investor Relations | ||
| Lars Green, Director | ||
| MSc MSc, Ex CFO | ||
| Lars Koeppler, Independent Director, Employee Representative |
Novozymes Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novozymes a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.28 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 14.47 B | |||
| Shares Outstanding | 276.6 M | |||
| Price To Earning | 34.25 X | |||
| Price To Book | 6.12 X | |||
| Price To Sales | 0.80 X | |||
| Revenue | 17.55 B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novozymes AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Novozymes Pink Sheet analysis
When running Novozymes' price analysis, check to measure Novozymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes is operating at the current time. Most of Novozymes' value examination focuses on studying past and present price action to predict the probability of Novozymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes' price. Additionally, you may evaluate how the addition of Novozymes to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |